Simvastatin in Waldenstrom's Macroglobulinemia

Status Terminated

Clinical Trial Summary

This research study seeks to find new ways to treat people with Waldenstrom's Macroglobulinemia (WM). The study is for participants with slow growing WM who otherwise might not need therapy for at least 3-6 months. Simvastatin is a drug approved by the FDA for lowering cholesterol. In test tube studies the study drug appears to have direct anti-cancer effect against WM tumor cells and mast cells.

Clinical Trial Description

OBJECTIVES:

To define objective response, time to progression and safety of Simvastatin in Waldenström's Macroglobulinemia.

STATISTICAL DESIGN:

For this phase II study, a single-stage design is used to evaluate the efficacy of Simvastatin. With a target enrollment of 30 participants, the 95% exact confidence bounds surrounding the response estimate will be no wider than +/- 19%. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00575965
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Terminated
Phase	Phase 2
Start date	November 2007
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02566265` - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients	Phase 2
Completed	`NCT00422656` - Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT00165295` - Sildenafil Citrate in Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT00150462` - Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies	Phase 1
Terminated	`NCT00142168` - CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia	Phase 2
Suspended	`NCT02439138` - Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia	Phase 2
Completed	`NCT01470196` - Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT00250926` - Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia	Phase 2
Terminated	`NCT03225716` - A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia	Phase 1
Terminated	`NCT01744912` - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies	Phase 1
Completed	`NCT02363439` - Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401	Phase 1/Phase 2
Completed	`NCT00976248` - Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT00919139` - S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.	N/A
Completed	`NCT01614821` - Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia	Phase 2
Active, not recruiting	`NCT01078974` - Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia	Phase 1
Completed	`NCT00481871` - Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies	Phase 1/Phase 2
Completed	`NCT00142116` - Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia	Phase 2
Completed	`NCT02092909` - Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia	Phase 1/Phase 2
Completed	`NCT00807677` - A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies	Phase 1
Completed	`NCT01046006` - Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia	Phase 2